Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
173
resultados
Última actualización
02/11/2026 [10:52:00]
Resultados 50 a 75 de 173
Resumen de: US20260315440A1
0000 The present disclosure relates to a method for treating or preventing an inflammation-mediated disease (IMD) selected from liver cancer, glioma, ovarian cancer, lung cancer, bladder cancer, gallbladder cancer, liver damage, fatty liver, hepatitis, liver fibrosis, pulmonary fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic stroke, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, and diabetes, including administering to a patient the compound of formula (I) or a salt thereof.
0000
Resumen de: AU2025249013A1
The present disclosure provides methods and compositions for the treatment of Tauopathies, including Alzheimer's Disease (AD) and Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP-17), by inhibiting expression of the MAPT gene. Aspects of the disclosure provide engineered inhibitory RNA agents, e.g., siRNA, miRNA, and antisense oligonucleotides, that knock down endogenous mutated or wild-type MAPT transcripts in neuronal cells in a subject. Expression vectors encoding the engineered inhibitory RNA agents, e.g., in an AAV vector, are also provided.
Resumen de: EP4821489A2
The present invention relates to a pharmaceutical composition useful for prevention or treatment of diabetes, beta-cell function preservation, high blood pressure, hyperlipidemia, obesity, non-alcoholic steatohepatitis or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as it comprises a sustained-release microsphere comprising semaglutide, a pharmaceutically acceptable salt, hydrate or solvate thereof, and thereby, it can effectively inhibit fatal side-effects by preventing initial burst of a drug and comprise a high content of drug compared to a particle size, and therefore, it can minimize the patient's pain and inflammatory reaction that may occur during administration.
Resumen de: WO2025122121A2
The present invention relates to a method (100) of synthesizing novel multi¬ effective urea/thiourea compounds which provide simultaneous inhibition of cholinesterase (AChE) and monoamine oxidase (MAO) enzymes known to play roles in Alzheimer's disease (AD); can interact with Ap peptides and/or P amyloid plaque; provide neuroprotective effect by reducing oxidative damage; and to the synthesized compounds and the biological activities they exhibit.
Resumen de: EP4822355A2
0001 Disclosed herein are methods based on the identification of reduced Hsp70 levels in PBMC samples serving as a biomarker for diseases presenting with a reduced level of Hsp70, such as lysosomal storage diseases, neurodegenerative diseases and muscular diseases.
Resumen de: PH12021500006A1
Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aá protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aá protofibril antibody is BAN2401.
Resumen de: AU2025249084A1
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.
Resumen de: US20260308585A1
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene for methods of using such iRNA to inhibit expression of C5 and to treat subjects having ALS.
Resumen de: WO2026212776A1
Antisense oligonucleotides that suppress expression CCDC146 are provided. Suppressing CCDC146 with an ASO disclosed herein shows no toxicity and substantially completely rescues amyotrophic lateral sclerosis (ALS)-associated survival defects in neurons derived from sporadic ALS patients and from carriers of the ALS-associated G4C2-repeat expansion within C9ORF72. Methods for therapeutic treatments against ALS or other neurological diseases are provided based on use of ASOs targeting CCDC146.
Resumen de: WO2026213050A1
Provided herein are compounds and pharmaceutical compositions comprising said compounds for treating agitation in a subject with Alzheimer's disease. Also, provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of fatty acid amide hydrolase (FAAH) and/or monoacylglycerol lipase (MAGL).
Resumen de: WO2026213260A1
Provided are methods of administering ION859 for reducing LRRK2 RNA and/or reducing LRRK2 protein in a human subject in need thereof. Also provided are methods of administering ION859 for reducing LRRK2 RNA and/or reducing LRRK2 protein in a human subject having Parkinson's Disease. The Parkinson's Disease may be LRRK2 mediated Parkinson's disease (i.e., Parkinson's disease associated with a causative LRRK2 genetic mutation) or non-LRRK2 mutation mediated Parkinson's disease (i.e., Parkinson's disease not associated with a causative LRRK2 genetic mutation).
Resumen de: US20260308542A1
0000 The present application relates to a novel therapeutic agent for treating Parkinson's disease and a method for treating Parkinson's disease using the same.
Resumen de: WO2026209986A1
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with Tau protein aggregates, including, but not limited to, Alzheimer's disease (AD). The present invention also relates to, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with Tau protein aggregates.
Resumen de: WO2026213117A1
In one aspect, methods for treating a subset of subjects suffering from schizophrenia/schizoaffective disorder exhibiting negative symptoms and/or cognitive deficits that include a) identifying a subject having increased inflammation connected with redox imbalance of olfactory epithelia, and b) treating the identified subject for schizophrenia and/or a schizoaffective disorder. In further aspects, methods of treating subjects with schizophrenia and related psychotic disorders include administration of Nrf2 activators. In further aspects, methods are provided for diagnosing, prognosing, and defining a treatment in response to nasal examination, including Alzheimer's disease and/or cognitive impairment.
Resumen de: US20260306543A1
Described herein, inter alia, are compositions and methods of use (e.g., treating Parkinson's Disease and/or reducing the immune response due to needle trauma during cell transplantation) for administering a population of regulatory T (TREG) cells and/or a population of midbrain dopamine (mDA) cells to the brain of a subject.
Resumen de: US20260306683A1
0000 Provided are labeled antibody conjugates for use in a method of diagnosing ALS or monitoring drug therapy and/or progression of ALS by in vivo detecting and tracing misfolded SOD1 by immunoimaging in a subject, compositions and kits comprising said conjugates and methods of in vivo immunoimaging of superoxide dismutase (SOD1) useful as a marker of amyotrophic lateral sclerosis (ALS) or efficacy of drug therapy of ALS in subject using these conjugates. Furthermore, SOD1-antibodies specific for misfolded and/or aggregated SOD1 are provided for use in treatment of bone and/or joint related diseases.
Resumen de: US20260306585A1
0000 The present disclosure relates to decreasing pathological neuroinflammation, particularly neuroinflammation associated with tauopathy and neurodegeneration. These pathologies can include Alzheimer's disease, certain types of dementia, Pick's disease, and ganglioglioma. Certain effects of decreasing pathological neuroinflammation may include a reduction in brain atrophy, a reduction neurodegeneration, a reduction in the interaction microglia and the brain parenchyma.
Resumen de: US20260308142A1
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical composition in the preparation of a drug for treating 5-HT2A receptor-related diseases. The diseases include non-motor symptoms caused by Parkinson's disease: delusions, hallucination, depression, anxiety, cognitive impairment and sleep disorders; dementia-related mental diseases; severe depression; or negative symptoms of schizophrenia, etc.
Resumen de: US20260306426A1
0000 Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, agitation associated with Alzheimer's disease, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Resumen de: US20260305670A1
A method for treating, attenuating the progression, or delaying the onset of clinical symptoms, of Alzheimer's disease or non-Alzheimer's includes administering a therapeutically effective amount of a composition comprising tahina and probiotic bacteria to a subject. The composition is formulated for oral administration; and the tahina has been microfluidized by passing through a fixed-geometry homogenization channel at a pressure of at least 5000 PSI.
Resumen de: US20260306517A1
The present disclosure relates to safe and effective subcutaneously administered treatments for advanced Parkinson's disease.
Resumen de: AU2025241870A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: EP4818163A1
The present disclosure belongs to the technical field of medicine, and particularly discloses a polycyclic compound as represented by formula I and use thereof. The polycyclic compound of the present disclosure has a structure as represented by formula I, and definitions of each group and substituent are as described in the specification. The compound of the present disclosure can be used for treating or preventing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, progressive multiple sclerosis, and amyotrophic lateral sclerosis.
Resumen de: EP4818330A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein rhereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Nº publicación: EP4818185A1 07/10/2026
Solicitante:
SHANGHAI BAOCHENG TAILAI TECH CO LTD [CN]
Shanghai Baocheng Tailai Technology Co., Ltd.
Resumen de: EP4818185A1
The present application relates to the field of medicine, and specifically relates to a crystal form A and crystal form B of 20(S)-protopanaxadiol, a preparation method therefor and the use thereof. The crystal form A and crystal form B provided in the present application are different from the existing known crystal forms of 20(S)-protopanaxadiol, each have a distinct profile, can be perfectly reproduced, have good bulk density, fluidity and stability, and good characteristics in terms of fighting depression, anxiety, and cognitive disorder, preventing and/or treating Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and treating diseases such as tumors or cardiovascular diseases, and have broad application prospects in the drug development of 20(S)-protopanaxadiol.
BOPI
Sede Electrónica
